Rosetta Genomics Signs Two Deals for MicroRNA Tests | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Rosetta Genomics today announced two collaborations to advance its microRNA-based diagnostic tests.

The Rehovot, Israel-based company has signed agreements with Tel Hashomer Medical Research Infrastructure and Services and Carmel Medical Center, both also based in Israel, to develop and validate Rosetta's miRNA-based tests for indications related to its Gen 3 products.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.